Table 3.
Antimicrobial usage by SARS-COV-2 and testing status
| Antimicrobial n (% of total antimicrobials) |
Not tested for SARS-CoV-2 (n = 452,024) |
Tested for SARS-CoV-2 | |
|---|---|---|---|
| SARS-CoV-2 negative (n = 124,927) |
SARS-CoV-2 positive (n = 17,049) |
||
| Total number of antimicrobialsa | 225,692 (100%) | 133,735 (100%) | 31,981 (100%) |
| Antibacterial | 211,088 (93.5%) | 125,811 (94.1%) | 29,828 (93.3%) |
| Cephalosporin | 61,468 (27.2%) | 37,514 (28.1%) | 9142 (28.6%) |
| Ceftriaxone | 32,198 (14.3%) | 20,081 (15.0%) | 5864 (18.3%) |
| Cefepime | 13,201 (5.8%) | 10,463 (7.8%) | 2647 (8.3%) |
| Macrolides | 14,200 (6.3%) | 12,883 (9.6%) | 7482 (23.4%) |
| Azithromycin | 13,632 (6.0%) | 12,642 (9.5%) | 7461 (23.4%) |
| Glycopeptides | 37,961 (16.8%) | 23,586 (17.6%) | 4254 (13.3%) |
| Vancomycin | 37,955 (16.8%) | 23,585 (17.6%) | 4254 (13.3%) |
| Beta-lactam/beta-lactamase inhibitors | 31,642 (14.0%) | 17,997 (13.5%) | 3065 (9.6%) |
| Piperacillin/tazobactam | 24,729 (11.0%) | 14,145 (10.6%) | 1981 (6.2%) |
| Tetracyclines | 6668 (3.0%) | 5585 (4.2%) | 2038 (6.4%) |
| Carbapenems | 7684 (3.4%) | 5068 (3.8%) | 1145 (3.6%) |
| Fluoroquinolones | 14,171 (6.3%) | 7119 (5.3%) | 800 (2.5%) |
| Antivirals | 8055 (3.6%) | 3918 (2.9%) | 1574 (4.9%) |
| Neuraminidase inhibitors | 2748 (1.2%) | 823 (0.6%) | 950 (3.0%) |
| Antifungals | 6549 (2.9%) | 4006 (3.0%) | 579 (1.8%) |
aPatients could have more than one prescribed antibiotic